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Abstract
Rare coding variants of the microglial triggering receptor expressed on myeloid cells 2
(TREM2) confer an increased risk for Alzheimer's disease (AD) characterized by the pro-
gressive accumulation of aggregated forms of amyloid β peptides (Aβ). Aβ peptides are
generated by proteolytic processing of the amyloid precursor protein (APP). Heterogene-
ity in proteolytic cleavages and additional post-translational modifications result in the
production of several distinct Aβ variants that could differ in their aggregation behavior
and toxic properties. Here, we sought to assess whether post-translational modifications
of Aβ affect the interaction with TREM2. Biophysical and biochemical methods revealed
that TREM2 preferentially interacts with oligomeric Aβ, and that phosphorylation of Aβ
increases this interaction. Phosphorylation of Aβ also affected the TREM2 dependent
interaction and phagocytosis by primary microglia and in APP transgenic mouse models.
Thus, TREM2 function is important for sensing phosphorylated Aβ variants in distinct
aggregation states and reduces the accumulation and deposition of these toxic Aβ species
in preclinical models of Alzheimer's disease.
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1 | INTRODUCTION
Progressive accumulation of amyloid-β (Aβ) in form of extracellular
plaques along with intracellular deposition of hyperphosphorylated tau
protein in neurofibrillary tangles (NFT) are classical pathological hallmarks
of Alzheimer's disease (AD) (d'Errico & Meyer-Luehmann, 2020; Haass &
Selkoe, 2007; Hyman et al., 2012; Selkoe & Hardy, 2016). Aβ deposits
can also be detected intracellularly, particularly inside of neurons (Gouras
et al., 2010; Gouras et al., 2012; Kumar et al., 2013; Wirths et al., 2009)
and within the vasculature of the brain (Huang et al., 2021; Spangenberg
et al., 2019; Thal et al., 2008; Thal et al., 2009). Aβ peptides can undergo
post-translational modifications that alter aggregation and neurotoxic
characteristics and might thereby modulate the pathogenesis of AD
(Barykin et al., 2017; Kummer & Heneka, 2014). For example, N-terminal
truncation and formation of pyroglutamate at position 3 of the Aβ pep-
tide strongly promotes aggregation, and pyroglutamate modified Aβ spe-
cies are abundant in AD brain (Saido et al., 1995; Schilling et al., 2008).
Phosphorylation of Aβ at serine 8 also promotes aggregation into oligo-
meric and fibrillar assemblies (Kumar et al., 2011), while phosphorylation
at serine 26 leads to formation of stable neurotoxic oligomers (Kumar
et al., 2016).
During disease progression, brain-resident microglia cluster around
extracellular Aβ plaques to prevent further growth or deposition thereby
limiting neuritic dystrophy (Condello et al., 2015). Microglia depletion also
altered parenchymal plaque development and promoted Aβ deposition in
cortical blood vessels (Spangenberg et al., 2019).
Recent studies identified sequence variants in the triggering receptor
expressed on myeloid cells 2 (TREM2) that are associated with an
increased risk for several neurodegenerative disorders such as AD
(Guerreiro, A. Wojtas, et al., 2013; Jonsson et al., 2013). TREM2 binds
anionic ligands, including certain phospholipids and apolipoproteins
(Bailey et al., 2015; Kober & Brett, 2017; Yeh et al., 2016). In addition,
TREM2 has also been shown to bind Aβ, and affect its clearance and
aggregation (Kober et al., 2020; Lessard et al., 2018; Vilalta et al., 2021;
Zhao et al., 2018; Zhong et al., 2018). However, little is known about
how post-translationally modified Aβ variants in various aggregation
states are handled by microglia and whether this is TREM2 dependent.
In this study, we demonstrate that posttranslational modifications
of Aβ differentially affect the binding to TREM2. Furthermore, we
report that TREM2 is involved in the differential internalization of
modified Aβ variants by microglia, and the characteristic deposition in
brains of transgenic mouse models of AD.
2 | METHODS
2.1 | Processing of Aβ peptides
The synthetic Aβ(1–42) and Aβ(3–42) peptide variants were obtained
from PSL, GmbH. Synthetic Biotin-LC-Aβ(1–42) (LC: 6-carbon long
chain) was obtained from AnaSpec. The synthetic Aβ peptides used in
this study showed greater than 95% purity by HPLC (data available on
request). The reconstitution of Aβ peptide variants was done by
adding 10 mM NaOH directly to the vial to make a stock solution of
230 μM followed by sonication for 5 min, aliquoted and snap-frozen.
Biotin-LC-Aβ(1–42) was reconstituted with DMSO and biolayer inter-
ferometry (BLI) assay buffer (consisting of 20 mM HEPES and 1 M
NaCl) thus giving a stock concentration of 100 μM, aliquoted and
snap-frozen.
For the preparation of Aβ oligomers we used two different
methods:
2.1.1 | Method 1
For the dot blot, and BLI experiments, we used oAβ(1–42) preparation
made by gently mixing freshly prepared Aβ(1–42) variants separately
with a suitable concentration of Biotin-LC-Aβ(1–42) to make the final
concentration of 23 μM in PBS (pH 7.4) followed by incubation at
37C for 3 h (Vilalta et al., 2021).
2.1.2 | Method 2
For the pulldown, and cellular binding and phagocytosis experiments, we
followed protocol to prepare oAβ as described previously (T. Kim
et al., 2013). Briefly, monomeric Aβ stock was diluted to 100 μM in PBS
and incubated at 23C for 16 h followed by an incubation at 4C for
24 h. The preparation was further centrifuged at 16,000g and the super-
natant aliquoted, flash frozen in liquid nitrogen and stored at 20C.
2.2 | Transmission electron microscopy
oAβ prepared using method 1 were characterized by negative stain-
transmission electron microscopy (TEM) as described by Anderson
et al. (2010). Briefly, 5–10 μl of oAβ at a concentration of 1 μM were
placed onto a freshly glow-discharged (by Glow discharge cleaning
system: PELCO easiGlow™ Glow Discharge System), carbon-coated
formvar, copper grid-400mesh (Electron microscopy sciences,
#CF400-CU). After 2 min, the sample solution was wicked off with fil-
ter paper, the grid rinsed with deionized water, and 5 μl of 2% (wt/
vol) phosphotungstic acid stain (pH 7.0) was placed on the grid. After
1 min, the staining solution was wicked away and the grid air-dried.
The negatively stained sample was then examined by using Talos
L120C (Thermo Fischer Scientific) at an acceleration voltage of
120 kV imaged with 4 k  4 K Ceta CMOS camera at x45,000. Repre-
sentative images are shown in Figure S1 a and b.
2.3 | Cell culture
2.3.1 | Culture of HEK293 Flp-In cells
HEK293 Flp-In and the sTREM2-WT expressing HEK293 Flp-In
cells were cultured in growth medium GlutaMAX™ (DMEM containing
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high glucose [4.5 g/L], phenol red, sodium pyruvate additive, 10 mM
HEPES), supplemented with 10% heat-inactivated fetal calf serum (FCS),
1% penicillin and streptomycin (P/S) solution, and 100 μg/ml hygromycin
in incubators maintained at 37C and 5% CO2 (Ibach et al., 2021). Using
the QuikChange-II kit (Agilent Technologies), site directed mutagenesis
was carried out according to the manufacturer's instructions in order to
introduce the stop codon at aa158 of full length TREM2 construct. The
generation of stable cell line was described previously (Ibach et al., 2021).
Briefly, the cells were cultured until 70%–80% confluency and washed
with DPBS. Co-transfection was carried our using mammalian Flp-In™
host cells with a 9:1 ratio of pOG44 coding for Flp recombinase and
pcDNA5/FRT plasmid DNA containing sTREM2 (aa1–aa157) sequence
using Lipofectamine 2000 (Thermo Fisher Scientific) in a transfection
medium (OptiMEM, Thermo Fisher Scientific). After 24 h, the medium
was replaced by medium containing 100 μg/ml Hygromycin B for selec-
tion of single cell clones by limiting dilution. Clones were screened by
detection of secreted Trem2 in the supernatant.
2.3.2 | Culture of Expi293F™ cells
Expi293F™ cells were grown in suspension with serum free Free-
Style™ expression medium (Thermo Fisher Scientific) and were kept
at 37C and 8% CO2.
2.3.3 | Culture of WT and TREM2T66M primary
microglia cells
The cells were isolated by the previously described method (Giulian &
Baker, 1986). Briefly, brains from neonatal mice were stripped of the
meninges and dissociated using mechanical shearing and trypsin (Life
Technologies). Cells of two brains were plated on poly-L-lysine (PLL,
Sigma-Aldrich) coated T75 culture flasks (Greiner bio-one) and cultivated
in DMEM (Gibco by Thermo Fisher Scientific) supplemented with 10%
FCS and 1% P/S (Gibco). On the next day cells were washed three times
with DPBS (Gibco) to remove cellular debris and cultured with DMEM
supplemented with 10% FCS, 1% P/S and 1% L929 conditioned medium
as a source of growth factors. After 7–10 days loosely attached mature
microglia were shaken off the astrocytic layer with a repetition of the
harvesting procedure all 2–3 days for up to three times. For experiments,
primary microglia were seeded on poly-D-lysine (PDL, Sigma-Aldrich)
coated glass cover slips at a density of 100,000/well into 24 well plates
and allowed to adhere overnight in serum-free DMEM complemented
with 1% N-2 supplement (Gibco).
2.4 | TREM2 ectodomain purification
2.4.1 | sTREM2 for the dot blot experiments
For the dot blot assay, cell supernatant from three 15 cm dishes of
HEK293 Flp-In controlk or sTREM2-WT expressing HEK293 Flp-In
cells was collected after 24 h of incubation. Saturated solution of
ammonium sulphate (AS) was made (3.9 M at 0C) and the total pro-
tein was precipitated with 40% AS solution. Because the addition of
AS acidifies the solution, a 1 M Tris–HCl buffer (pH 8.0) was added to
the supernatant so that the final concentration was 50 mM
(Burgess, 2009; Wingfield, 2001). The mixture is gently mixed and
incubated for 1 h on ice and then centrifuged for 30 min at 4C at
16,000 rcf. The supernatant was discarded and the pellet was
resuspended in 5 ml of 1X PBS and this solution was used for dot blot
assay (Data S1a for the immunoblot).
2.4.2 | TREM2 ectodomain for BLI studies
A cDNA construct encoding residues aa19–aa143 of TREM2 with a
C-terminal His-tag was subcloned into a mammalian expression vec-
tor, pHLSec (Aricescu et al., 2006) and transfected into Expi293 cell
line using polyethylenimine (PEI) (Backliwal et al., 2008) as the trans-
fection reagent. Endotoxin-free chemicals and plastic ware were used.
Recombinant protein was purified from the culture medium using Ni-
Excel and size exclusion chromatography followed by Endo Hf (NEB, #
P0703L) treatment and the buffer exchange to BLI assay buffer by
using Superose® 6 Increase 10/300 GL (GE Healthcare, #29-0915-96)
and the final concentration of the protein was determined by using
Biophotometer (Eppendorf) (Vilalta et al., 2021). The obtained TREM2
was detected with Anti-TREM2 antibody (Data S1b for the
immunoblot).
2.4.3 | sTREM2-Fc and Fc for pull down
experiments
sTREM2-Fc1 vector was generated by inserting human sTREM2
(aa1–aa157) sequence into the pFUSE-hIgG1-Fc1 expression vector.
Expression of the Fc-fusion proteins was done following the protocol
described by Fang et al. (2017). Briefly, one day before transfection,
cells were seeded at 1.5 million viable cells per milliliter (mvc/ml) in
fresh medium. The next day, cells were transfected at 3 mvc/ml in half
of the final volume with a 1 mg/ml linear 40 kDa PEI Max solution
(Polysciences, #24765-1) and the respective DNA (1 μg/ml) in a 6:1
ratio. Efficiency of transfection was further increased by addition of
0.1% Pluronic® F-68 (Thermo Fisher Scientific, #24040032). After
24 h the transfection mix was diluted with fresh medium 1:1 and sup-
plemented with 0.5 M valproic acid (Sigma Aldrich, #VPA P4543) to a
final concentration of 3.5 mM. The conditioned media were collected
after 4–5 days. Following centrifugation, filtration and pH adjustment
the media were loaded on a HiTrap™ Protein G HP 1 ml column and
affinity purified via FPLC. Eluted fractions were neutralized by addi-
tion of 1 M Tris (pH 9.0). Concentration and buffer exchange against
PBS was performed by ultrafiltration with a 10 kDA MWCO column
(Sartorius, Göttingen). The concentration of the purified proteins was
determined by a spectrophotometer measuring the absorbance at
280 nm (Data S1c for the immunoblot).
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2.5 | Dot blot assay
Monomer rich fractions of Aβ were prepared from freshly reconstituted
Aβ stocks by dilution to 23 μM in ice cold PBS and ultracentrifugation
at 4C at 100,000g for 1 h. Aβ in the supernatant was considered as
monomer rich preparation, and characterized by western immunoblot
(please refer Figure S1c). Oligomer rich Aβ (oAβ) preparations were
obtained as described in Method-1. Then, 2 μl from each of above equi-
molar preparations from the stock solution (23 μM) were spotted on
nitrocellulose (NC) membranes, and the membranes were allowed to
dry. The NC membranes were then incubated with concentrated cell
supernatant overnight at 4C. The membranes were washed with TBS-
T (3  5 min) and then blocked with Odyssey Blocking Buffer (LI-COR
Bioscience) for 1.5 h at RT. The membranes were then incubated over-
night in primary antibody (monoclonal antibody 4B2A3 for detection of
TREM2) at 4C. The NC membranes were then washed with TBS-T
(3  5 min) and incubated with LI-COR fluorescent secondary antibody
for 1 h at RT, washed with TBS-T (3  5 min), then once with TBS
(5 min) and imaged with Odyssey® CLx (LI-COR Biosciences). To detect
Aβ on the same membranes after detection of bound TREM2, the dot
blots were washed with TBS-T (3  5 min) followed by incubation with
4G8 antibody overnight to detect Aβ variants. The NC membranes were
washed with TBS-T (3  5 min) and incubated with LI-COR fluorescent
secondary antibody for 1 h at RT, washed with TBS-T (3  5 min), then
once with TBS (5 min) and developed with LI-COR Odyssey® CLx (LI-
COR Biosciences). (please refer Data S1d for the original dot blots
cropped for Figure 1b).
2.6 | Bio-layer interferometry (BLI) studies
The aggregation state of the different Aβ variants (prepared by
Method-1) was controlled by TEM; (Figure S1a). No significant
changes in the size distribution of oligomers formed by unlabeled Aβ,
Biotin-LC-Aβ or by mixtures of unlabeled Aβ and Biotin-LC-Aβ (at a
ratio of 20:1) was observed (Figure S1b) indicating that the conjuga-
tion of Aβ with biotin does not affect the average size of oligomers.
Mixtures of Biotin-LC-Aβ with the different N-terminal truncated or
post-translationally modified Aβ variants (also at 20:1 ratio) also
yielded very similar size distribution of oligomers between 8 and
55 nm. Only the oligomer preparation with pSer8-Aβ also contained
larger oligomers with sizes between 55 and 90 nm. This was observed
for both, Aβ(1–42) and Aβ(3–42) variants. However, also for pSer8-Aβ
variants, >95% of the oligomers were in the size range of 8–55 nm.
For BLI studies with TREM2 ectodomain by using Octet RED384
(Forte Bio), we used 5% of Biotin-LC-Aβ(1–42) for mixing with Aβ var-
iants compared with only Biotin-LC-Aβ(1–42) (unpublished data). Fur-
ther, we optimized the concentration of already mixed oAβ to
immobilize onto the biosensors. Initial experiments revealed that 5%
of 1 μM Biotin-LC-Aβ mixed with 1 μM of oAβ when immobilized onto
the streptavidin (SA) biosensors (Forte Bio #18-0009) showed a simi-
lar loading and binding as compared with 100%, 5% Biotin-LC-Aβ
(Data S2a,b) and hence the same concentration of mixed Aβ variants
was used in this study. In addition to this, we also checked the differ-
ential loading of oAβ onto the SA biosensors in which oAβ(1–42)
pSer26 showed higher loading as compared with other variants
(Data S2c).
For BLI kinetic measurements, Streptavidin (SA) biosensors
were hydrated with 220 μl assay buffer (20 mM HEPES,
500 mM NaCl, 0.1% BSA, 0.02% Tween 20 (pH 7.4) for 30 min
(96 well plate). Further, biosensors were exposed to 220 μl
buffer in order to determine the initial baseline. The Biosensors
were exposed to oligomer rich preparations obtained from mix-
tures of the respective Aβ variants and Biotin-LC-Aβ in 20:1
ratios. Biosensors were then exposed to 220 μl of assay buffer
for 450 s for another baseline measurement. The biosensors
were exposed to 220 μl assay buffer containing TREM2
ectodomain at different concentrations (1, 2, 5, and 10 μM) pre-
pared in BLI assay buffer for 60 s to measure association. The
biosensors were then exposed to 220 μl of assay buffer for
150 s to measure dissociation. The kinetic constants of BLI were
obtained with four different concentrations of TREM2
ectodomain and data was aligned at the y-axis and smoothed by
Savitzky–Golay filtering. Curves were processed by adjusting to
BLI control buffer, and curve fitting was performed using 2:1
heterogenous ligand as a model due to the heterogenicity of Aβ.
KD1 and KD2 values provide the measure of the relative coeffi-
cients for dissociation and binding, wherein KD1 measures inter-
action that occupies the highest percentage of the binding
surface area and KD2 characterizes the secondary interaction,
determined mathematically by the Octet Data Analysis software.
2.7 | Immunoprecipitation of Aβ using sTREM2-Fc
For assessing differential binding of mAβ and oAβ variants to TREM2,
2 μg of sTREM2-Fc or hIgG1-Fc were pre-coupled to magnetic Pro-
tein G beads (SureBeads™, Bio-Rad) for 20 min at 23C. The coupled
beads were then further incubated with 2 μg of the oAβ preparation
(prepared by Method-2) for 1 h at 23C in PBS buffer containing 0.1%
Tween-20 (PBS-T). After precipitation and subsequent thorough
washing steps, the bound proteins were eluted from the beads by
addition of 20 mM glycine solution at pH 2.5. Finally, the eluate was
neutralized with 1 M Tris–HCl pH 8 and boiled at 95C in Laemmli
buffer before being subjected to immunoblot analysis. For a quantita-
tive assessment, this protocol was slightly altered by reducing the
amount of beads (300 μg) and Aβ (1 μg) while increasing the amount
of sTREM2-Fc and hIgG1-Fc to 10 μg to ensure complete saturation
of the beads with recombinant protein.
2.8 | SDS-page
Protein separation was performed using the XCell SureLock®Mini-Cell
or XCell4 SureLock® Midi-Cell SDS-PAGE system (Invitrogen™,
#V601020). Samples prepared in 5x SDS sample buffer and boiled at
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95C for 5 min were separated according to their molecular weight on
a precasted discontinuous Bis-Tris NuPAGE Novex 4%–12% gel
(Invitrogen™, #V601020). Separation was achieved by using 1x
NuPAGE™ MES SDS Running Buffer and a constant voltage of 120 V
for 1 h. Gels were subsequently analyzed by western immunoblot
analysis (Ibach et al., 2021; Kumar et al., 2021).
2.9 | Western immunoblotting
Proteins separated by SDS-PAGE were transferred to NC membranes as
described previously (Ibach et al., 2021), at constant current of 400 mA
and for 2 h. The membranes were then blocked for 1 h at constant agita-
tion with a 5% milk solution, followed by incubation of the membrane
over night at 4C and constant agitation (orbital shaker) with a solution of
the primary antibody in 1x TBS-T. The next day, the membranes were
washed (3  5 min) followed by incubation with respective secondary
antibody conjugated either to horseradish peroxidase or a fluorophore for
1 h at RT. The membranes were washed again (3  5 min) followed by
detection of the protein with the Chemidoc XRS Imager (BioRad) or
Odyssey® CLx (LI-COR Biosciences).
2.10 | Binding and phagocytosis assays
oAβ variants prepared as described in Method 2 were incubated with
primary microglia from WT or TREM2T66M transgenic mice. Cells were
incubated with 1 μM of Aβ oligomers in DMEM GlutaMAX™ at 37C
F IGURE 1 Differential interaction of TREM2 with modified Aβ variants. (a) Pictorial illustration of various PTMs of Aβ peptides used for binding
assessment in this study. (b) Representative dot blot of various mAβ and oAβ variants spotted on the NC membrane followed by incubation with
concentrated supernatant of control HEK293 Flp-In cells or transgenic sTREM2 expressing stable HEK293 Flp-In cells. (c) Quantification of ratio of
signal intensity of sTREM2 detected with anti-TREM2 antibody and respective Aβ variants detected with 4G8 antibody. The average values of ratio
from experimental triplicate of Aβ(1–42) variants are represented as “●” while of Aβ(3–42) variants are represented as “▲.” * or ^represents a
comparison of Aβ(1–42) or Aβ(3–42) variants respectively. (n = 3, unpaired t test with Welch correction, *or p̂ < .05, **or^̂p < .01). (d) Schematics of BLI
strategy using streptavidin (SA) biosensors. Biotinylated oAβ variants immobilized on SA biosensor to assess the interaction with TREM2 ectodomain at
concentrations of 1, 2, 5, 10 μM. (e, f) Representative association/dissociation curves of varying TREM2 ectodomain concentrations and calculated
KD1/KD2 values of TREM2 ectodomain binding with oAβ variants (see Table S1 for other set of values). n = 2, which includes repetition of the entire
experiment including preparation and dilution of oAβ oligomers, KD-equilibrium dissociation constant
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and 5% CO2 for 2 h before they were fixed, permeabilized and sta-
ined. Coverslips were mounted on glass slides and observed using a
VisiScope CSU-W1 spinning disk confocal microscope. As a control,
cells were also pretreated with DMSO at a final concentration less
than 0.01% and 10 μM Cytochalasin D (CytoD) dissolved in DMSO,
keeping the final concentration of DMSO less than 0.01% for 30 min
to block actin polymerization and thereby macropinoctytosis before
changing to the assay conditions described before ( Kim et al., 2017;
Xiang et al., 2016).
In order to assess the binding of oAβ variants prepared as described
in Method-2, primary microglia from WT and TREM2T66M transgenic
mice seeded as described above were treated with 1 μM of oAβ in
DMEM GlutaMAX™ and incubated on ice for 2 h followed by fixation
and staining. In order to assess the uptake of bound Aβ, primary microglia
were first incubated with 1 μM of oAβ in DMEM GlutaMAX™ on ice for
2 h. After this, the cells were washed and further incubated at 37C and
5% CO2 for 2 h. The cells were then fixed, permeabilized and stained.
2.11 | Immunocytochemistry of primary microglia
Cells were fixed for 15 min in 4% paraformaldehyde (PFA) before
permeabilization with 0.1% Triton-X100 (PBS) for 5 min. After block-
ing with 3% BSA in PBS-T, 100 μl of primary antibody in 1% BSA was
added to each coverslip and incubated at RT for 1 h. Coverslips were
subsequently washed three times with 0.5% BSA in PBS-T. After-
wards, respective secondary antibodies in 1% BSA solution were
added and coverslips were incubated for 1 h at RT in the dark,
followed by another three washing steps. Finally, the coverslips were
mounted on a microscopy slide using VECTASHIELD® antifade
mounting medium with DAPI (Vector lab, #H-1200).
2.12 | Transgenic mice
Wild-type and homozygous TREM2T66M crossed to APPKM670/
671NL; PS1ΔE9 transgenic mice were obtained from Taconic Biosci-
ences GmbH, and were all of the C57BL/6 genetic background. Mice
were housed under standard conditions at 22C and a 12 h light–dark
cycle with free access to food and water. Animal care and handling of
these mice was performed according to the Declaration of Helsinki
and approved by the local ethical committees (LANUV NRW 84–
02.04.2017.A226).
APP695KM670/671NL; PS1L166P transgenic mice with endoge-
nous TREM2 or the TREM2 deletion (TREM2/) mice were
described previously (Parhizkar et al., 2019; Turnbull et al., 2006).
2.13 | Immunofluorescence analysis of mouse
brains
Mouse brain samples were processed as described previously
(Kumar et al., 2021; Parhizkar et al., 2019), and 20–25 μm sections
collected in PBS for staining. For immunofluorescence (IF) staining,
heat-induced sodium citrate antigen retrieval (pH 6.0) using
10 mM sodium citrate with 0.05% Tween-20 at 95C for 30 min or
80% formic acid treatment for 8 min (Gerth et al., 2018) was
employed depending on various Aβ species. Sections were then
washed once with PBS. For X-34 staining, sections were treated
with 100 μM of X-34 prepared in 60% PBS/40% EtOH mix (pH
was adjusted with 1 M NaOH) for 10 min at RT (Parhizkar
et al., 2019; Styren et al., 2000). The sections were washed briefly
with 60% PBS/40% EtOH and subjected to permeabilization with
0.3% Triton X-100 for 30 min before blocking for 2 h in 5% NHS
and 2.5% BSA prepared in 1xPBS. Mouse on Mouse Blocking
Reagent (Vector laboratories, #MKB-2213) was used for primary
antibodies generated in mouse or rat at a dilution of
1 drop/1000 μl. Primary antibodies (Table S2) were added and the
sections kept at 4C overnight. After adding the appropriate sec-
ondary antibodies (Table S2), tissue sections were mounted onto
slides by using VECTASHIELD® Hardset™ antifade mounting
medium (Vector lab, #H-1400) or VECTASHIELD® antifade mount-
ing medium with DAPI (Vector laboratories, #H-1200).
2.14 | Confocal imaging and data analysis
Images were acquired using VisiScope CSU-W1 spinning disk confocal
microscope and VisiView Software (Visitron Systems GmbH). Laser
and detector settings were maintained constant for the acquisition of
each immunostaining. For all analyses, at least two images were
acquired using x20, x40W or x63W (W: water immersion) objective at
2048  2048 pixels, with z-step size of 1 μm.
For quantification of microglial binding and uptake of Aβ, IntDen
was calculated by manually drawing border around randomly selected
Aβ positive microglia. Representation of ratio of Aβ positive microglia/
total microglia was done by manually counting Aβ positive cells and
automatically counting DAPI positive total cells for 10 images/
experiment (5 images per coverslips and the experiments were in
duplicates).
For analysis of internalized pSer26-Aβ in transgenic mouse brain,
number of plaque associated microglia were manually counted in
500  500 μm areas of somatosensory cortex (SSC) on 1–2 indepen-
dently stained sections and then represented as the ratio of
pSer26-Aβ positive microglia/total Iba1 positive microglia.
2.15 | Statistical analysis
Statistical analyses were performed using Prism (GraphPad Soft-
ware). Unless otherwise stated, two-sided, unpaired student's
t tests with Welch's correction was used to determine the statisti-
cal difference between groups in analyses that only required single
comparisons. The degree of significance between groups is repre-
sented as *p < .05, **p < .01, ***p < .001, ****p < .0001, and
nsp > .05.
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2.16 | Randomization and blinding
The primary microglia experiments and the immunofluorescence anal-
ysis of mouse brains were initially performed blinded with coded
slides. However, complete randomization was not possible with the
stainings of mouse brain sections with a microglial marker depicting
microglial clustering. Following the completion of the analysis, the
groups were unblinded to perform statistics.
2.17 | Data collection
The BLI data were acquired and analyzed by using Octet RED384 and
data analysis 9.0 (Forte Bio). The TEM images were acquired by using
Talos L120C (Thermofischer Scientific). Confocal images were
acquired by using VisiScope CSU-W1 spinning disk confocal micro-
scope and VisiView Software (Visitron Systems). The western immu-
noblotting data were acquired by using by enhanced
chemiluminescence using Chemidoc XRS Imager (BioRad) or Odys-
sey® CLx (LI-COR Biosciences). Microsoft Excel was used to organize
and to calculate the averages of each repeated experiment. Graph Pad
(Prism v7.0) was used to build graphs and perform statistical analyses
presented throughout the manuscript.
3 | RESULTS
3.1 | Differential binding of TREM2 to post-
translationally modified Aβ species
In order to investigate the interaction of TREM2 with different Aβ
species (Figure 1a), we first assessed the binding of soluble TREM2
(sTREM2) to monomeric (mAβ) and oligomeric (oAβ) forms of distinct
post-translationally modified and non-modified Aβ variants in dot blot
assays. For this, different Aβ variants in monomeric and oligomeric
form were spotted onto Nitrocellulose (NC) membranes and incu-
bated with sTREM2 obtained from conditioned media of transgenic
cells expressing a TREM2 variant with a stop codon at position
158 thereby representing the soluble TREM2 ectodomain that is
physiologically generated by proteolytic processing of full-length
TREM2 (Feuerbach et al., 2017; Schlepckow et al., 2017; Thornton
et al., 2017; Wunderlich et al., 2013). sTREM2 bound to the different
Aβ species was detected by an anti-TREM2 antibody (4B2A3). This
antibody recognizes an epitope within the stalk region of TREM2
(aa 131–148) (Ibach et al., 2021), thereby avoiding possible competi-
tion with ligands bound to the ligand binding domain of sTREM2.
Consistent with previous reports, TREM2 showed strongly increased
interaction with oligomeric as compared with monomeric Aβ variants
(Figures 1b,c and S1). Oligomers formed by Aβ variants phosphory-
lated at Ser8 (pSer8-Aβ) or Ser26 (pSer26-Aβ) showed significantly
increased interaction with TREM2 as compared with non-modified,
nitrated or pyroglutamate-modified variants. With monomeric forms,
pSer26-Aβ also showed strongly increased binding to TREM2 as
compared to non-modified Aβ or otherwise modified Aβ variants.
However, it should be noted that pSer26-Aβ has the highest tendency
to form oligomeric assemblies (Kumar et al., 2016), and it cannot be
excluded that pSer26-Aβ formed some oligomeric assemblies during
this assay.
To validate these findings with an independent method, we uti-
lized BLI (Figure 1d). The different Aβ variants were mixed with
Biotin-labeled-Aβ at a ratio of 20:1 and oligomerized as described pre-
viously (Vilalta et al., 2021). Oligomer preparations were immobilized
on streptavidin biosensors (Figure 1d) and kinetic binding assays per-
formed using purified TREM2 ectodomain at different concentrations
(1, 2, 5, and 10 μM). BLI kinetic studies also revealed increased binding
of the TREM2 ectodomain to oligomers that contained pSer8-Aβ or
pSer26-Aβ (Figure 1e,f). The lowest binding was measured for nitrated
Aβ3NTyr(10) as compared with non-modified Aβ (Figure 1e). Oligo-
meric pyroglutamate modified Aβ (pEAβ) also showed lower binding
to the TREM2 ectodomain as compared with non-modified Aβ.
(Figure 1f, Table S1).
Pull-down assays from mixtures containing monomeric and oligo-
meric forms of Aβ using sTREM2-Fc fusion proteins further demon-
strated that sTREM2 preferentially binds to oligomeric Aβ assemblies.
Again, highest binding was detected for phosphorylated Aβ oligomers
as compared with non-modified Aβ species (Figure 2a,b). The com-
bined data from different biochemical and biophysical assays demon-
strate that phosphorylation of Aβ at Ser8 or Ser26 increased binding
to TREM2 in particular for oligomeric Aβ assemblies.
3.2 | TREM2 dependent binding and phagocytosis
of modified Aβ species by primary microglia
To further characterize the interaction of Aβ species with TREM2 and
its functional implications, we used primary microglia from wild-type
(WT) mice expressing endogenous TREM2 and mice with the
TREM2T66M knock-in (KI) mutation. The TREM2T66M mutation is asso-
ciated with Nasu Hakola disease (NHD) or frontal lobe dementia
(FTD) and strongly impairs ectodomain folding and cell surface trans-
port of the receptor thereby causing a loss of function (Kleinberger
et al., 2014; Le Ber et al., 2014). First, we assessed the binding of
phosphorylated and non-modified Aβ species to the plasma mem-
brane of primary microglia from WT mice by incubation of cells on ice
to halt endocytosis (Tamboli et al., 2008; Wesen et al., 2017). While
the membrane-association of pSer8-Aβ was lower, that of pSer26-Aβ
was increased as compared with binding of non-modified Aβ
(Figure 3a,b), indicating phosphorylation-site and phosphorylation-
state specific interaction of Aβ with the microglial surface. Decreased
binding of pSer8-Aβ was observed for the two length variants of Aβ,
1–42 and 3–42. Since Aβ(1–42)pSer26 could not be chemically syn-
thesized, the analysis was restricted to Aβ(3-42)pSer26 and compared
with non-modified Aβ(3–42) and Aβ(3-42)pSer8 species, respectively.
Importantly, binding of the different Aβ species was reduced by about
50% in TREM2T66M expressing microglia as compared with TREM2
WT expressing microglia (Figure 3a,b). On one hand, these results
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demonstrate the involvement of functional TREM2 in the binding of
the different Aβ species, and on the other hand, support previous
reports showing that the association of Aβ to microglia could also
involve additional proteins or lipids present at the cell surface (Verdier
et al., 2004; Yu & Ye, 2015). When cells were further incubated at
37C upon binding of Aβ to the surface, we observed differential
uptake of bound Aβ depending on the phosphorylation state
(Figure 3c,d). While the amount of internalized pSer8-Aβ was lower,
the amount of internalized pSer26-Aβ was higher as compared with
that of unphosphorylated Aβ. In addition, the number of Aβ positive
microglia was lower for pSer8-Aβ exposed cells, but higher for
pSer26-Aβ exposed cells as compared with the number of microglia
that internalized unphosphorylated Aβ (Figure S2a,b). The
phosphorylation-state dependent internalization of Aβ variants in
TREM2 WT microglia might involve differences in the aggregation
and/or conformation of pSer8-Aβ and pSer26-Aβ (Kumar et al., 2011;
Kumar et al., 2012; Kumar et al., 2016). Phosphorylation-state depen-
dent uptake of Aβ was also observed when cells were exposed to Aβ
without a precedent binding period, and was reduced by
cytochalasin D, indicating the involvement of phagocytosis
(Figures 4a,b and S2). Again, the phagocytosis of the different Aβ spe-
cies was strongly reduced in microglia from TREM2T66M KI mice, dem-
onstrating that the differential uptake of phosphorylation-state
variants of Aβ depends on functional TREM2 (Figure 4). Co-staining
with Lamp-1 revealed partial localization of internalized Aβ in lyso-
somal compartments (Figures 3 and 4). Lysosomal localization was
particularly pronounced for pSer26-Aβ, indicating lysosomal accumu-
lation of this phosphorylated Aβ form. These results indicate that the
phosphorylation state of Aβ affects its TREM2 dependent binding and
phagocytosis by microglia. However, in addition to the differential
interaction with TREM2, peculiar differences in the aggregation char-
acteristics and conformation of the phosphorylation-state variants of
Aβ could contribute to the differential interaction and uptake by
microglia.
3.3 | TREM2 deletion leads to altered deposition
of phosphorylated Aβ variants
To further investigate the role of TREM2 in the interaction of dif-
ferent phosphorylated Aβ species with microglia in vivo, we used
APP transgenic mice that express endogenous TREM2 or mice
with a TREM2 knockout mutation. Similar to previous studies
(Wang et al., 2015; Yuan et al., 2016; Zhao et al., 2018), we also
observed decreased microglial clustering around X-34 positive
plaques in brains of TREM2/ mice as compared with TREM2+/+
mice (Figure 5a,b). Interestingly, mice homozygous for the
TREM2T66M mutation also showed reduced clustering around X-34
positive plaques that contain fibrillar Aβ (Figure 5c,d). Immuno-
staining of brain sections with antibodies against the microglial
marker protein Iba1 together with phosphorylation-state specific
antibodies for Aβ with Ser8 in phosphorylated or non-modified
state (nmAβ) revealed that X-34 positive plaques also contained
Ser8-phosphorylated and unphosphorylated (nmAβ) species that
are surrounded by microglia in TREM2 WT mice (Figure 5). In con-
trast, brains of TREM2/ (Figure 5a,b) or TREM2T66M expressing
mice (Figure 5c,d) showed increased radial extensions of fibrillar
Aβ that are intermingled with microglial processes thereby forming
F IGURE 2 Increased interaction of TREM2 with oligomeric phosphorylated Aβ variants. (a) Representative western immunoblot of samples
from pull-down (PD) experiments for oAβ with sTREM2-Fc or with Fc alone as a control. Efficient pre-coupling of sTREM2-Fc or Fc alone to
protein-G magnetic beads is confirmed by the depletion of these proteins from the buffer solution in the supernatant after pre-incubation of
beads (“Beads sup” lanes). A preferential pull-down of oAβ by sTREM2 is indicated by robust signals for aggregated forms of Aβ in the “Eluate”
fractions detected in the upper regions of the gels, while large portions of mAβ remains in the supernatant after the pull-down (“Sup after PD”).
(b) Box and whiskers plot of IntDen of signals for the monomer band or oligomeric forms. Values were normalized to the respective input. Each
dot represents an independent experiment. All data represent mean ± SEM (n = 4 for Aβ(1–42) or n = 5 for Aβ(3–42) variants, unpaired t test
with Welch correction, *p < .05, **p < .01, nsp > .05)
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mesh-like structures with various degrees of compaction (indicated
by arrow heads, Figure 5). Very similar observations on the mor-
phology of Aβ deposits and interactions with microglia in brains of
TREM2+/+ and TREM2/ mice were also made when Aβ was
detected by a monoclonal antibody (82E1) that detects the
N-terminus of Aβ independent on its phosphorylation state
(Figure S3). These findings are consistent with the function of
TREM2 to restrict plaque size or growth (Wang et al., 2015; Yuan
et al., 2016). It is important to note that TREM2 positive plaque
associated microglia also restrict pSer8-Aβ deposits, which could
F IGURE 3 Involvement of functional TREM2 in surface binding and subsequent uptake of phosphorylated Aβ variants by primary microglia.
(a) Representative immunocytochemical staining images of primary microglia from wild-type (WT) and TREM2T66M mice, and (b) plot showing the
normalized IntDen of oAβ positive cells after treatment with 1 μM oAβ for 2 h at 0C followed by fixation and staining. (c) Representative
immunocytochemical staining images of primary microglia from WT and TREM2T66M mice, and (d) plot representing the uptake of bound oAβ
levels calculated from IntDen of oAβ positive cells after treatment with 1 μM oAβ variants for 2 h at 0C, followed by washing and incubating at
37C for 2 h followed by fixation and staining. Microglial cells were stained using Iba1 antibody (white) while Aβ was stained via the generic
antibody 4G8 (red). Lamp1 antibody was employed as a lysosomal marker (green) (Scale bar = 10 μm, 63xW). IntDen of oAβ (either 1–42 or
3–42) for WT primary microglia was set as 1 for normalization of values for pSer8 and pSer26-phosphorylated oAβ species and accordingly values
for TREM2T66M were calculated. Each dot represents the average value of normalized IntDen/experiment. Data represent mean ± SEM (n = 300
cells/group, experimental n = 3, unpaired t test with Welch correction, *or p̂ < .05, **or ^̂p < .01 ***p < .001 for comparison of WT and
TREM2T66M, A.U.-arbitrary units). r̂epresents comparison of phosphorylated Aβ variants with Aβ (1–42 or 3–42) treated to WT primary microglia
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be due to enhanced TREM2 binding. However, little if any
pSer8-Aβ was detected within microglia (Figure 5a,c).
In contrast to pSer8-Aβ, pSer26-Aβ was abundant within
microglia (Figure 6), consistent with the observed increased bind-
ing and TREM2-dependent internalization by microglia (see
Figures 1–4). Deposition of pSer26-Aβ was detected in the two
independent APP transgenic mouse models used in this study
(Figure 6). However, in contrast to fibrillar Aβ detected by X-34 or
pSer8-Aβ, pSer26-Aβ species were only faintly detected in the
core of dense Aβ plaques and rather appeared as small deposits in
close proximity of extracellular plaques (Figure 6a,c). Co-
immunostaining of pSer26 with Iba1 and Lamp1 revealed lyso-
some associated pSer26-Aβ within plaque associated microglia in
the different APP transgenic mouse models expressing TREM2+/
+, that was strongly reduced in APP transgenic mice deficient of
TREM2 (Figure 6a,b) or expressing the TREM2T66M KI mutation
(Figure 6c,d).
4 | DISCUSSION
Here, we show the differential interaction of TREM2 and post-trans-
lationally modified Aβ species with oligomers formed by phosphory-
lated Aβ variants binding most avidly to TREM2. In addition, our data
demonstrate the involvement of TREM2 in the binding and uptake of
distinct phosphorylation-state variants of Aβ by microglia in vitro and
in vivo.
Alternative proteolytic processing of APP and post-translational
modifications results in the formation and deposition of a variety of
Aβ peptides during the pathogenesis of AD (Barykin et al., 2017;
Kummer & Heneka, 2014). Among the different modifications, phos-
phorylation at Ser8 promotes the fibrillization of Aβ, while phosphory-
lation at Ser26 rather decreases fibrillization, but stabilizes oligomeric
assembly (Kumar et al., 2011; Kumar et al., 2016; Rezaei-Ghaleh
et al., 2016). In addition, the phosphorylation at Ser8 increased the
stability of Aβ against degradation by microglial cells (Kumar
F IGURE 4 Differential phagocytosis of phosphorylated Aβ variants by primary microglia. (a) Representative immunocytochemical staining
images of primary microglia from wild-type (WT) and TREM2T66M mice after pretreatment with vehicle (DMSO) or CytoD (Figure S2a) treatment
for 30 min followed by treatment with 1 μM oAβ for 2 h at 37C. Microglial cells were stained using Iba1 antibody (white), and Aβ by antibody
4G8 (red). Lamp1 antibody was employed as a lysosomal marker (green) (Scale bar = 10 μm, 63xW). (Scale bar = 10 μm, 63xW). (b) Plot
representing the internalization of different oAβ variants by primary microglia from WT and TREM2T66M mice calculated by the IntDen of
internalized Aβ. Each dot represents the average value of normalized IntDen of Aβ positive microglia/experiment. Data represent mean ± SEM
(n = 300 cells/group, experimental n = 3, unpaired t test with Welch correction, **p < .01, ***p < .001 for comparison of WT and TREM2T66M,
A.U.-arbitrary units)
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et al., 2012). pSer8-Aβ could also seed aggregation of
unphosphorylated Aβ (Hu et al., 2017; Kumar et al., 2011). Consistent
with previous findings, we found that TREM2 binds much stronger to
oligomeric Aβ assemblies than to monomeric Aβ (Lessard et al., 2018;
Zhao et al., 2018). Furthermore, despite having distinct aggregation
kinetics and stability, both phosphorylated Aβ species in oligomeric
form showed the strongest interaction with TREM2.
We also show phosphorylation-state and phosphorylation-site
specific uptake of Aβ by primary microglia. Notably, while the
uptake of pSer8-Aβ was decreased, the internalization of
pSer26-Aβ was increased as compared with that of non-modified
Aβ. The uptake of all Aβ species was significantly reduced in
microglia expressing the TREM2T66M loss of function mutation
that is associated with NHD and frontal lobe degeneration
(Guerreiro, Bilgic, et al., 2013; Guerreiro, Lohmann, et al., 2013;
Paloneva BM et al., 2001). This mutation causes misfolding and
strongly decreases the expression of TREM2 at the cell surface
(Kleinberger et al., 2014). Thus, these data indicate that cell sur-
face localized TREM2 is important for the regulation of Aβ phago-
cytosis. However, additional components of the microglial surface,
F IGURE 5 Decreased microglial barrier function alters deposition of pSer8-Aβ and nmAβ in brains of TREM2 deficient mice (a, b)
Representative IF images of extracellular plaques stained for pSer8-Aβ (a) and nmAβ (b) in 12 M-APP/PS1L166P-TREM2+/+ and TREM2/ mice.
Fibrillar Aβ was detected by X-34 and microglia were stained with Iba1. (c, d) Representative IF images of extracellular plaques stained for
pSer8-Aβ (c) and nmAβ (d) in 12 M-APP/PS1ΔE9-TREM2 and APP/PS1ΔE9-TREM2T66M mice. Fibrillar Aβ was detected by X-34 and microglia
were stained with Iba1. Dotted white boxes indicate the area shown at higher magnification while the arrowheads indicate the mesh-like
structures that surround the plaques of varying compaction in TREM2/ or TREM2T66M mice. (Scale bar = 20 μm, 40xW)
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including receptor proteins and membrane lipids could also be
involved in the interaction and uptake of different Aβ variants
(Mandrekar et al., 2009; Verdier et al., 2004; Yu & Ye, 2015). In
addition, peculiar effects of phosphorylation at Ser8 and Ser26 on
the conformation and aggregation of Aβ could also contribute to
the differential interaction with TREM2 and handling of the pep-
tides by microglia (Kumar et al., 2011; Kumar et al., 2012; Kumar
et al., 2016).
F IGURE 6 Loss of TREM2 function leads to decreased microglial pSer26-Aβ deposits in brains of TREM2 transgenic mice. (a) Representative IF
images of SSC regions of 12 M-APP/PS1L166P-TREM2+/+ and TREM2/ mice co-stained for pSer26-Aβ along with the lysosomal marker Lamp1, and
the microglial marker Iba1 (Scale bar = 50 μm, 40xW, dotted white boxes indicate the area shown at higher magnification). (b) Quantification of microglia
per cortical region of interest (ROI) showed a decreased number of pSer26-Aβ positive microglia (indicated with arrowheads) in the 12 M-APP/PS1L166P-
TREM2/ compared with TREM2+/+ mice (t[7.976]= 8.615, ****p < .0001). (c) Representative IF images of pSer26-Aβ stained SSC of 12 M-APP/
PS1ΔE9-TREM2 and TREM2T66M mice along with the lysosomal marker, Lamp1 and microglial marker, Iba1 (Scale bar = 50 μm, 40xW, dotted white
boxes indicate the area shown at higher magnification). (d) Quantification of microglia per cortical region of interest (ROI) showed a decreased number of
pSer26-Aβ positive microglia (indicated with arrowheads) in the 12 M-APP/PS1ΔE9-TREM2T66M compared with APP/PS1ΔE9-TREM2 mice (t
[3.577]= 4.739,*p= .0118). All data represent mean ± SEM. (n = 5 animals (6b) or n = 3 animals (6d), unpaired t test with Welch correction)
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To assess the role of TREM2 in the deposition of phosphorylated
Aβ species in vivo, we used two different APP/PS1 transgenic mouse
models crossed to TREM2 WT, TREM2/ mice or TREM2T66M mice.
Consistent with previous findings (Boon et al., 2020; Kumar
et al., 2013; Kumar et al., 2016), pSer8-Aβ and pSer26-Aβ showed dif-
ferential deposition. While pSer8-Aβ deposits primarily in the core of
extracellular plaques, pSer26-Aβ showed limited deposition in these
lesions (Boon et al., 2020; Kumar et al., 2021). Importantly, pSer8-Aβ
was hardly detected within microglia, but mainly deposited as fibrillar
Aβ in the plaque core which also contained N-terminally non-modified
Aβ. These data are in line with the fibrillization-promoting effect of Aβ
phosphorylation at Ser8 (Kumar et al., 2011). Thus, although microglia
could bind Ser8-Aβ containing aggregates, their internalization might
be restricted by the high compaction of these peptides within the
plaque core. In contrast, pSer26-Aβ was prominently detected within
plaque-associated microglia. Since the phosphorylation at Ser26 pre-
vents fibrillization but stabilizes oligomeric states of Aβ (Kumar
et al., 2016; Rezaei-Ghaleh et al., 2014), soluble pSer26-Aβ assemblies
might efficiently bind to TREM2 and be internalized.
Pyroglutamate modified and nitrated Aβ did not show increased
binding to TREM2. In contrast to phosphorylation, pyro-glutamination
and nitration do not change the overall charge of Aβ. Since TREM2
preferentially binds anionic ligands (Kober & Brett, 2017; Ulrich
et al., 2017; Walter, 2016), the additional negative charges introduced
by phosphorylation, likely contribute to the increased association of
phosphorylated Aβ with TREM2. However, additional effects of dis-
tinct post-translational modifications on the conformation and aggre-
gation status of Aβ assemblies could also modulate binding to TREM2.
Further, distinct post-translational modifications could affect phago-
cytosis and degradation pathways of these species as well as their
deposition and neurotoxic properties independent on TREM2. Indeed,
phosphorylation, nitration, and pyro-glutamination of Aβ differentially
affect the aggregation and neurotoxicity of Aβ in in vitro systems
without the involvement of TREM2 (Dammers et al., 2015; Kumar
et al., 2016; Kummer et al., 2011; Nussbaum et al., 2012). Thus, it will
be interesting to further dissect the relative contribution of TREM2
and microglia in the deposition and neurotoxic properties of the dif-
ferent Aβ species in the brain during the pathogenesis of AD.
It should be noted that the deposition of non-modified,
pyroglutamate-modified, and phosphorylated Aβ species follows a
specific sequence in the brain with initial deposits not containing
detectable amounts of pyro-glutaminated or phosphorylated Aβ spe-
cies (Gerth et al., 2018; Rijal Upadhaya et al., 2014; Thal
et al., 2019). While pyro-glutaminated Aβ variants can also be
detected in a subset of cases without clinical signs of dementia,
detection of phosphorylated Ser8-Aβ is mainly restricted to cases
with clinical manifestation of AD (Rijal Upadhaya et al., 2014; Thal
et al., 2019). As mentioned above, pSer26-Aβ species show limited
deposition in extracellular plaques, but are also found intra-
neuronally and in vascular deposits (Kumar et al., 2016; Kumar
et al., 2021). Thus, post-translational modifications likely contrib-
ute to the specific accumulation and differential deposition in the
brain and could represent interesting targets for AD therapy.
Indeed, recent data from phase 2 clinical trials revealed positive
effects of antibodies specifically recognizing pyroglutamate modi-
fied Aβ (Donanemab) in early AD (Mintun et al., 2021). Thus, it will
be important to further assess the potential of targeting phosphor-
ylated Aβ species in AD therapy and prevention.
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